Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANXENE vs TRANXENE SD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal inhibition.
Anxiety disorders,Short-term relief of anxiety symptoms,Alcohol withdrawal syndrome,Adjunctive treatment for partial seizures
Anxiety disorders,Short-term relief of anxiety symptoms,Acute alcohol withdrawal,Preoperative sedation (adjunctive),Partial seizures (adjunctive, off-label)
7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.
Oral: 11.25-22.5 mg once daily (sustained-release formulation).
Terminal elimination half-life of the active metabolite desmethyldiazepam is 30-200 hours (mean ~100 hours); parent drug clorazepate is rapidly hydrolyzed and has negligible half-life. Accumulation occurs with repeated dosing, leading to delayed peak effects and prolonged sedation.
Terminal elimination half-life of nordazepam (active metabolite) is 30–100 hours (mean 50 hours); clorazepate itself has a short half-life (~2 hours) due to rapid conversion.
Hepatic via oxidative metabolism; primarily by CYP3A4 and CYP2C19 to active metabolite nordazepam, then to oxazepam and others. Also undergoes glucuronidation.
Hepatic via conjugation and oxidative metabolism; primary metabolite is desmethyldiazepam (active); CYP450 involvement (CYP3A4 and CYP2C19).
Primarily renal (80-90% as conjugated metabolites, including oxazepam and desmethyldiazepam); biliary/fecal excretion accounts for <10%.
Renal excretion of conjugated metabolites, with less than 1% unchanged drug; approximately 30% excreted in feces via biliary elimination.
Clorazepate and desmethyldiazepam: 95-98% bound to albumin.
97–98% bound to albumin; nordazepam is highly protein-bound.
Clorazepate: 0.2-0.3 L/kg. Desmethyldiazepam: 0.5-1.5 L/kg (large Vd indicates extensive tissue distribution).
0.9–1.4 L/kg for clorazepate; nordazepam Vd approximately 0.8–1.2 L/kg, indicating extensive tissue distribution.
Oral: nearly 100% (prodrug completely hydrolyzed in gastric acid to desmethyldiazepam). Intramuscular: erratic and incomplete (approximately 50-70% bioavailability due to variable absorption).
Oral: 100% (prodrug fully converted); no parenteral formulation.
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50% and use with caution.
GFR <10 m L/min: Reduce dose by 25-50% and consider avoidance due to accumulation of active metabolites.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh Class B or C: Reduce dose by 50% or avoid use; monitor for excessive sedation.
Children 9-12 years: 7.5 mg orally twice daily; increase to 7.5 mg three times daily if needed. Not recommended under 9 years.
Not recommended for patients <18 years due to lack of safety and efficacy data.
Initiate at 3.75 mg orally 1 to 2 times daily; titrate slowly to avoid sedation and falls.
Reduce initial dose by 50% (e.g., 11.25 mg once daily or less), titrate slowly, and monitor for falls and cognitive impairment.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate alternative treatment options.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Risk of dependence and withdrawal seizures with abrupt discontinuation,CNS depressant effects may impair driving or operating machinery,Use caution in hepatic impairment,Avoid in pregnancy (risk of neonatal withdrawal and floppy infant syndrome),Potential for anterograde amnesia,Elderly patients at increased risk for adverse effects
Risk of abuse, misuse, and addiction,Dependence and withdrawal reactions,CNS depressant effects (impairment of driving/operating machinery),Respiratory depression (especially with opioids),Glaucoma (narrow-angle) use cautiously,Suicidal ideation (pre-existing depression)
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe hepatic impairment,Pregnancy (especially first trimester),Breastfeeding,Concomitant use with opioids unless alternative treatments are inadequate
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concomitant use with opioids (in some contexts)
No specific food interactions. Grapefruit juice does not significantly affect metabolism. Fatty meals may delay absorption of oral clorazepate, but overall bioavailability not affected.
Food may delay but does not significantly reduce absorption. Avoid grapefruit juice as it may inhibit CYP3A4, increasing nordazepam levels. Avoid alcohol completely.
FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to physical dependence and withdrawal symptoms in the neonate, including floppy infant syndrome, respiratory depression, and feeding difficulties. Late pregnancy or near delivery: Risk of neonatal sedation, hypotonia, and withdrawal.
First trimester: Increased risk of congenital malformations (oral clefts) reported with benzodiazepine use; data specifically for clorazepate limited but class effect assumed. Second/third trimester: Exposure may cause fetal CNS depression, hypotonia, respiratory depression, and withdrawal symptoms (e.g., jitteriness, hypertonia) in neonates.
Excreted in human milk. M/P ratio not established. Case reports indicate low milk levels (approx 4-10% of maternal weight-adjusted dose) but infant accumulation possible due to long half-life. Benefits of breastfeeding should be weighed against potential risks of sedation and poor feeding in the infant. Monitor infant for drowsiness, poor suckling, and weight loss.
Clorazepate is excreted into breast milk; M/P ratio approximately 0.2. Infant exposure likely low but may cause sedation. Use with caution; monitor infant for drowsiness and poor feeding. Consider alternative if high maternal doses or prolonged use.
Due to increased volume of distribution and enhanced clearance, higher doses may be required during pregnancy to maintain efficacy, especially in the second and third trimesters. However, dose adjustment should be individualized and cautious because of potential fetal risks. Use the lowest effective dose for the shortest duration. Avoid high doses near term.
Increased volume of distribution and enhanced hepatic metabolism in pregnancy may lower serum clorazepate levels; consider dose increase if therapeutic effect inadequate. Avoid in first trimester if possible; use lowest effective dose in later trimesters. Taper gradually before delivery to minimize neonatal withdrawal.
TRANXENE (clorazepate) is a benzodiazepine prodrug that is decarboxylated in the stomach to the active metabolite N-desmethyldiazepam. Onset of action is relatively slow (1-2 hours) compared to diazepam. Due to its long half-life (up to 100 hours for active metabolite), accumulation is possible in elderly or hepatically impaired patients. Avoid in narrow-angle glaucoma. Abrupt discontinuation may precipitate withdrawal seizures.
TRANXENE SD (clorazepate dipotassium) is a long-acting benzodiazepine with a slow onset, making it less suitable for acute panic but effective for generalized anxiety. Its active metabolite, nordazepam, has a half-life of 40-100 hours, allowing once-daily dosing. Monitor for accumulation in elderly or hepatic impairment. Use with caution in patients with a history of substance abuse due to dependence risk.
Do not stop taking suddenly; taper under medical supervision to avoid withdrawal symptoms.,Avoid alcohol and other CNS depressants (e.g., opioids, sleep aids) as they increase sedation and respiratory depression risk.,May cause drowsiness, dizziness; avoid driving or operating machinery until effect is known.,Take with or without food. Do not crush or chew extended-release capsules.,Inform doctor if you have a history of substance abuse, liver disease, or glaucoma.,Use caution in elderly patients due to increased risk of falls and cognitive impairment.,Notify doctor immediately if you experience suicidal thoughts, unusual mood changes, or allergic reactions.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop abruptly; reduce dose gradually to avoid withdrawal symptoms (e.g., anxiety, insomnia, seizures).,Avoid alcohol and other CNS depressants (e.g., opioids, sedatives) as they increase sedation and respiratory depression risk.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how the drug affects you.,Report any unusual changes in mood, thoughts, or behavior (e.g., depression, suicidal thoughts).,Use effective contraception if of childbearing potential due to fetal harm risk; notify prescriber if pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANXENE vs TRANXENE SD, answered by our medical review team.
TRANXENE is a Benzodiazepine Anxiolytic that works by Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.. TRANXENE SD is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANXENE and TRANXENE SD depend on the specific clinical indication. These are both Benzodiazepine Anxiolytic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANXENE is: 7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.. The standard adult dose of TRANXENE SD is: Oral: 11.25-22.5 mg once daily (sustained-release formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANXENE and TRANXENE SD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANXENE is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimest. TRANXENE SD is classified as Category C. First trimester: Increased risk of congenital malformations (oral clefts) reported with benzodiazepine use; data specifically for clorazepate limited but class effect assumed. Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.